Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p
Abstract Understanding mechanisms of resistance to abiraterone, one of the primary drugs approved for the treatment of castration resistant prostate cancer, remains a priority. The organic anion polypeptide 1B3 (OATP1B3, encoded by SLCO1B3) transporter has been shown to transport androgens into pros...
Saved in:
Main Authors: | Roberto H. Barbier, Edel M. McCrea, Kristi Y. Lee, Jonathan D. Strope, Emily N. Risdon, Douglas K. Price, Cindy H. Chau, William D. Figg |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/e06fd1fa19174341a92b77d01fce5e9c |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
MicroRNA-579-3p Exerts Neuroprotective Effects Against Ischemic Stroke via Anti-Inflammation and Anti-Apoptosis
by: Jia J, et al.
Published: (2020) -
MicroRNA-579-3p Exerts Neuroprotective Effects Against Ischemic Stroke via Anti-Inflammation and Anti-Apoptosis [Retraction]
by: Jia J, et al.
Published: (2021) -
Acta Nº579
by: Banco Central de Chile
Published: (2019) -
Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
by: Ayşe Demirci, et al.
Published: (2021) -
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
by: Mamta Parikh, et al.
Published: (2021)